earnings
confidence high
sentiment neutral
materiality 0.80
Regeneron Q1 revenue up 19% to $3.6B; non-GAAP EPS $9.47; gross margin guidance cut
REGENERON PHARMACEUTICALS, INC.
2026-Q1 EPS reported
$6.75
revenue$3,605,400,000
- Total revenues $3,605M (+19% YoY); GAAP EPS $6.75, non-GAAP EPS $9.47.
- EYLEA HD U.S. net sales $468M (+52%); EYLEA HD+EYLEA total U.S. down 10% to $941M.
- Dupixent global net sales (Sanofi) up 33% to $4.9B; new approvals for CSU in children and AFRS.
- New $3.0B share repurchase authorized; $803M bought back in Q1; dividend $0.94/share.
- FY2026 GAAP gross margin guidance reduced to 77%-78% from 79%-80% due to Limerick plant disruption.